Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment

Pras, Elisabeth; Willemse, Pax H.B.; Canrinus, Alof A.; Bruijn, H.W.A. de; Sluiter, Wim J.; Hoor, Klaske A. ten; Aalders, Jan G.; Szabo, Bernard; Vries, Elisabeth G.E. de

doi:10.1016/s0360-3016(01)01805-3

Cited by 58 publications

(51 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our test data is in agreement with the results of other researchers regarding the diagnostic usefulness of antigen SCC in this malignancy [26][27][28]. Moreover, its prognostic significance, both for recurrence-free and overall survival, has been confirmed by other researchers in the early stages of cervical cancer [29].…”

Section: Discussionsupporting

confidence: 92%

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Ławicki

Będkowska

Gacuta-Szumarska

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:In this study, we compared plasma levels and the diagnostic utility of hematopoietic growth factors (HGFs) with SCC-Ag in cervical cancer patients in relation to control groups and cervical intraepithelial neoplasia (CIN) patients and healthy subjects. Pretreatment plasma levels of HGFs (SCF, GM-CSF, G-CSF and M-CSF) were determined by the use of immunoenzyme assay (ELISA), and SCC-Ag by chemiluminescent microparticle immunoassay (CMIA). Significantly different concentrations of GM-CSF, G-CSF and M-CSF were observed in the group of patients with cervical cancer and CIN compared to the healthy controls. Significant differences in plasma levels of GM-CSF and M-CSF between cervical cancer and benign lesions patients were also found. The HGFs and SCC-Ag diagnostic specificities received high values. The diagnostic sensitivity and the predictive value of a positive and negative test result were higher for M-CSF than for antigen SCC in the cancer group. The M-CSF area under the ROC curve (AUC) was the largest from hematopoietic cytokines and SCC-Ag. These results suggest the potential utility of M-CSF as a good candidate for a marker of cervical cancer as well as benign lesions of this organ (CIN).

show abstract

Section: Discussionsupporting

confidence: 92%

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Ławicki

Będkowska

Gacuta-Szumarska

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…However, it is still a matter of debate whether serum SCCA assay may represent a prognostic variable and be useful for earlier diagnosis of relapse (22,23). Most reports found CYFRA 21-1 to be a less sensitive serum tumor marker for squamous cell cervical cancer than SCCA (24)(25)(26). One-third of SCCA-negative patients are CYFRA 21-1 positive, and thus CYFRA 21-1 assay appears to be a useful supplementary test in a small subset of patients with squamous cell cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of Serum HMGB1 Levels in Early Detection of Recurrent Squamous Cell Carcinoma of Uterine Cervix: Comparison with Serum SCCA, CYFRA21-1, and CEA Levels

Sheng¹,

Du²,

Xiao-ling³

et al. 2009

Croat Med J

View full text Add to dashboard Cite

AimTo evaluate the clinical value of serum high mobility group box chromosomal protein 1 (HMGB1) levels in making the early diagnosis of recurrent cervical squamous cell carcinomas (CSCC) and compare it with the value of serum squamous cell carcinoma antigen (SCCA), cytokeratin fragment (CYFRA) 21-1, and carcinoembryonic antigen (CEA) levels.Methods Immunohistochemical staining of tissue from 64 patients with recurrent CSCCs, 72 patients with non-recurrent carcinoma, and 28 healthy participants was performed to determine the expression of HMGB1 protein. The serum levels of the 4 markers in 112 patients with recurrent CSCC, 174 patients with non-recurrent disease, and 128 healthy participants were measured by enzyme-linked immunosorbent assay. The receiver operating characteristic (ROC) curves were constructed and the area under the curve (AUC) was calculated. ResultsHigher immunostaining score was found in recurrent CSCC tissue sections than in non-recurrent CSCC sections. Serum HMGB1 levels in patients with recurrent CSCC were significantly higher than in patients with non-recurrent disease and healthy controls. The AUC of HMGB1, SCCA, CY-FRA21-1, and CEA was 0.816, 0.768, 0.703, and 0.625, respectively. HMGB1 had the best specificity and positive likelihood ratio (78.0% and 3.25, respectively), whereas SCCA had the best sensitivity and negative likelihood ratio (76.3% and 0.34, respectively). Parallel combined measurements increased the diagnostic sensitivity and serial combination increased the specificity. High serum HMGB1 levels were inversely correlated with disease-free survival (P = 0.009, Pearson χ 2 test) and overall survival (P = 0.018).Conclusion HMGB1 was overexpressed in recurrent CSCCs. Serum HMGB1 level could be a useful and specific marker for evaluating the disease recurrence and predicting prognosis in patients with CSCC. Serial combined measurements of serum HMGB1, SCCA, and CYFRA21-1 increased the diagnostic specificity, and parallel combined testing increased the diagnostic sensitivity.

show abstract

“…Raised SCC levels have been measured in 28-88% of patients with squamous cell cervical cancer [12,[18][19][20][21][22][23][24][25][26][27][28][29] ( Table 1). This wide range in positivity rates is mainly dependent on both the cut-off value chosen for the antigen and patient characteristics.…”

Section: Incidence Of Elevated Pre-treatment Serum Scc Levelsmentioning

confidence: 99%

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

Gadducci

Tana

Cosio

et al. 2008

Critical Reviews in Oncology/Hematology

138

127

View full text Add to dashboard Cite

Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment

Cited by 58 publications

References 43 publications

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Clinical Value of Serum HMGB1 Levels in Early Detection of Recurrent Squamous Cell Carcinoma of Uterine Cervix: Comparison with Serum SCCA, CYFRA21-1, and CEA Levels

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

Contact Info

Product

Resources

About